Mezavant (Mesalazine)

Mesalazine releases 5‑ASA directly onto the intestinal lining, where it blocks cyclooxygenase and lipoxygenase enzymes, reducing prostaglandin and leukotriene production. It also neutralises free radicals, helping to dampen local immune activation and lower mucosal inflammation.

The dosage of Mezavant is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. Physicians determine the appropriate strength, frequency, and duration, and patients should follow the prescribed regimen without alteration.

Safety data for mesalazine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks and discuss any concerns with the patient before prescribing.

To request Mezavant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant delivers mesalazine directly to the colon, offering a targeted approach similar to other 5‑ASA agents such as sulfasalazine. Compared with sulfasalazine, Mezavant avoids the need for bacterial activation and may have a lower incidence of sulfa‑related side effects, though individual response varies.

Mezavant tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Mezavant is taken orally, usually with a full glass of water. It can be swallowed whole or, if recommended by the prescriber, divided into multiple doses throughout the day to maintain steady drug levels in the intestinal tract.

Serious adverse events include myocarditis, severe liver injury, blood dyscrasias such as neutropenia, acute pancreatitis, and life‑threatening allergic reactions like anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, jaundice, unexplained fever, or severe skin reactions.

Mezavant is contraindicated in patients with known hypersensitivity to mesalazine, other 5‑ASA compounds, or any component of the formulation. It should also be avoided in individuals with severe sulfonamide allergy and used with caution in those with significant renal or hepatic impairment.